Pixium Vision announces positive long-term data from patients implanted with PRIMA, a state-of-the-art implantable chip. The data were presented at The Eye and The Chip – Virtual Event, held October 3-5, 2021.

• PRIMA implant is well tolerated and safe in patients 36 months after implantation
• Implant is highly stable with no lifetime deteriorations observed
• PRIMA can potentially provide meaningful visual acuity improvement

Pixium Vision announces today that the management team will participate in the 8th Annual Healthtech Investment Forum taking place on 5th and 6th of October, 2021, digitally. More information about the event can be found here.

To request one-on-one meeting with Pixium Vision please contact Guillaume van Renterghem at gvanrenterghem@lifesciadvisors.com.